ZEB2 and hepatocellular carcinoma: Sphere-formation and IC50 assays were conducted, and lnc-ZEB2-19 overexpression significantly inhibited the sphere-formation capability and IC50 value of HCC cells, whereas lnc-ZEB2-19 knockdown notably facilitated the efficiency of sphere formation and resistance to lenvatinib (Fig.2I, J).